Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Examine Radioactive Drugs Research Reg

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency is holding a Nov. 16 public meeting to discuss whether new guidance on the use of radioactive drugs for research purposes should be developed, or if the current reg should be revised.

You may also be interested in...



Radioactive Drugs Research Comment Period Reopened By FDA

The agency will accept comments for 60 days on its regulation of radioactive drugs for certain research uses. The additional comment period will allow for feedback in the context of a draft guidance on exploratory INDs released in April, FDA says.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel